Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.
Also called NCT06212648
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 253 participants
- Registry
-
NCT06212648
-
- Other papers using this trial's data
- Multicenter, Randomized, Double-Blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06212648. Randomized; double masking; primary purpose treatment. Start 2022-03-25 (actual); primary completion 2022-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
- Acronym
- SP-CAP-002
- Condition
- Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- SPC1001 High
- Intervention (Drug)
- SPC1001 Mid1
- Intervention (Drug)
- SPC1001 Mid2
- Intervention (Drug)
- SPC1001 Low
- Intervention (Drug)
- SPC3001
- Intervention (Drug)
- SPC4001
- Intervention (Drug)
- SPC4002
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Record details
- Record id
cardio:ct-nct06212648- Content hash
e47f57dd0e9d55578dd3ed04cc200c5f26f96e90fb18b1b17b1260523ed5178b